New Drug Admin System for Rare Eye Cancer
- A novel drug delivery system is offering new hope for patients battling metastatic uveal melanoma, a rare and aggressive form of eye cancer that often spreads to the...
- Uveal melanoma, the most common type of eye cancer in adults, originates in the uvea, the middle layer of the eye.
- The recent study,coordinated internationally,explored the benefits of percutaneous liver infusion,a technique that delivers chemotherapy directly to the liver.
New Liver Infusion Method Shows Promise for Uveal Melanoma
Table of Contents
A novel drug delivery system is offering new hope for patients battling metastatic uveal melanoma, a rare and aggressive form of eye cancer that often spreads to the liver. Early results from an international clinical trial indicate that percutaneous liver infusion can significantly improve outcomes compared to standard treatments.
Understanding Uveal Melanoma
Uveal melanoma, the most common type of eye cancer in adults, originates in the uvea, the middle layer of the eye. When this cancer metastasizes, it frequently targets the liver, leading to a poor prognosis. Treatment options for liver metastases of uveal melanoma have historically been limited and often ineffective, with systemic chemotherapy and other therapies presenting significant side effects, according to a letter published in *PMC*. (See: PMC10664426)
Percutaneous Liver Infusion: A Targeted Approach
The recent study,coordinated internationally,explored the benefits of percutaneous liver infusion,a technique that delivers chemotherapy directly to the liver. This method allows for higher doses of medication to be administered directly to the tumor while minimizing systemic side effects.
Percutaneous liver infusion involves isolating the liver with a system of catheters and balloons, allowing a high dose of chemotherapy to be delivered directly to the organ. The infused blood is then filtered before re-entering general circulation.
Clinical Trial Results
The Phase 3 clinical trial, known as FOCUS, compared percutaneous liver infusion using the chemotherapy drug melphalan to standard treatment protocols for metastatic uveal melanoma. the study, published April 7 in the journal *Annals of Surgical Oncology*, revealed a significant betterment in progression-free survival for patients receiving the liver infusion.
Patients treated with percutaneous liver infusion experienced an average progression-free survival of 9.1 months,compared to 3.3 months for those receiving standard treatment. The objective response rate, indicating tumor shrinkage, was also significantly higher at 27.5% compared to 9.4% in the control group. Furthermore, the disease control rate, reflecting the proportion of patients whose disease was stabilized or improved, jumped from 46.9% to 80.0% with the new treatment.
the study also showed an increase in overall survival, with patients receiving percutaneous liver infusion living an average of 18.5 months compared to 14.5 months in the standard treatment group.While some adverse reactions, primarily related to decreased blood cell counts, were reported, they were generally manageable with outpatient monitoring.
expert Commentary
Dr. Jonathan zager, a surgical oncologist, stated that the new treatment “offers hope to patients with a recognized cancer for the difficulty of its management,” according to a news release. He added that the study results demonstrate the treatment’s ability to control the disease at the hepatic level and provide patients with a therapeutic option that does not compromise their quality of life while extending survival.
future Research
Researchers are planning further studies to evaluate the therapy’s benefits and explore potential combinations with other emerging cancer treatments.
# New Hope for Uveal Melanoma: Percutaneous liver infusion
Here’s an informative guide on a promising new treatment for metastatic uveal melanoma,answering key questions about this innovative approach.
## What is Uveal Melanoma?
Uveal melanoma is the most common type of eye cancer in adults. It originates in the uvea, the middle layer of the eye.
## Why is Metastatic Uveal Melanoma Challenging to Treat?
When uveal melanoma spreads (metastasizes), it frequently enough targets the liver, which can lead to a poor prognosis. Historically, treatment options for liver metastases of uveal melanoma have been limited and frequently enough ineffective, with systemic chemotherapy and other therapies causing significant side effects.
## What is Percutaneous Liver infusion?
Percutaneous liver infusion is a targeted technique that delivers chemotherapy directly to the liver. This approach allows higher doses of medication to be administered to the tumor while minimizing systemic side effects.
## how Dose Percutaneous Liver Infusion Work?
The procedure involves isolating the liver using a system of catheters and balloons. This setup allows a high dose of chemotherapy to be delivered directly to the liver. The infused blood is then filtered before re-entering the general circulation.
## What Are the Key Benefits of This Approach?
The primary benefits of percutaneous liver infusion include:
- Delivering chemotherapy directly to the tumor site within the liver.
- Minimizing systemic side effects by targeting the treatment.
- Potentially improving outcomes compared to standard treatments.
## What Do Clinical Trial Results Show?
A Phase 3 clinical trial, the FOCUS trial, compared percutaneous liver infusion using the chemotherapy drug melphalan to standard treatment protocols for metastatic uveal melanoma. The results, published in the *Annals of Surgical Oncology*, highlighted significant improvements:
### Progression-Free Survival:
Patients treated with percutaneous liver infusion experienced an average progression-free survival of 9.1 months compared to 3.3 months with standard treatment. This means the cancer took longer to grow or spread in the treatment group.
### Objective Response Rate:
The objective response rate, which indicates tumor shrinkage, was substantially higher in the treatment group at 27.5% compared to 9.4%.
### Disease Control Rate:
The disease control rate, showing the proportion of patients whose disease was stable or improved, rose from 46.9% to 80.0% with the new treatment.
### Overall Survival
Overall survival also improved, with patients receiving percutaneous liver infusion living an average of 18.5 months compared to 14.5 months in the standard treatment group.
## Can You Summarize the key Differences?
here’s a table summarizing the key findings of the clinical trial:
| Metric | Percutaneous Liver Infusion | Standard Treatment |
|---|---|---|
| Progression-Free Survival (months) | 9.1 | 3.3 |
| Objective Response Rate | 27.5% | 9.4% |
| Disease Control Rate | 80.0% | 46.9% |
| Overall survival (months) | 18.5 | 14.5 |
## What are the Side Effects of Percutaneous Liver Infusion?
The study reported some adverse reactions, mainly related to decreased blood cell counts.However, thes were generally manageable with outpatient monitoring.
## What does an Expert say About this Treatment?
Dr. Jonathan zager, a surgical oncologist, stated that the new treatment “offers hope to patients with a recognized cancer for the difficulty of its management.” He added that the treatment can control the disease at the hepatic level and offers a therapeutic option that doesn’t compromise the patient’s quality of life while extending survival.
## What’s Next for This Treatment?
Researchers are planning further studies to evaluate the therapy’s benefits and explore potential combinations with other emerging cancer treatments.